These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22505536)

  • 41. HER-2/neu oncogene expression in advanced breast cancer.
    Krogerus LA; Leivonen M
    Cancer Detect Prev; 2001; 25(1):1-7. PubMed ID: 11270416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
    Tsai KB; Hou MF; Lin HJ; Chai CY; Liu CS; Huang TJ
    Kaohsiung J Med Sci; 2001 Feb; 17(2):64-76. PubMed ID: 11416960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
    Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
    Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
    Kuroda N; Kontani K; Kajikawa T; Taminato T
    Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
    Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
    Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients.
    Hoopmann M; Sachse K; Valter MM; Becker M; Neumann R; Ortmann M; Göhring UJ; Thomas A; Mallmann P; Schöndorf T
    Eur J Cancer Care (Engl); 2010 Nov; 19(6):809-15. PubMed ID: 20105224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER-2/neu diagnostics in breast cancer.
    Carney WP; Leitzel K; Ali S; Neumann R; Lipton A
    Breast Cancer Res; 2007; 9(3):207. PubMed ID: 17561991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.
    Witzel I; Thomssen C; Krenkel S; Wilczak W; Bubenheim M; Pantel K; Neumann R; Jänicke F; Müller V
    Int J Biol Markers; 2006; 21(3):131-40. PubMed ID: 17013794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
    Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
    Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
    Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
    Disis ML; Pupa SM; Gralow JR; Dittadi R; Menard S; Cheever MA
    J Clin Oncol; 1997 Nov; 15(11):3363-7. PubMed ID: 9363867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
    Wu JT; Astill ME; Gagon SD; Bryson L
    J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management].
    Mathelin C; Croce S; Rault S; Gharbi M; Eichler F; Gairard B; Coumaros G; Koehl C
    Presse Med; 2011 Feb; 40(2):126-37. PubMed ID: 21074348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR.
    Gschwantler-Kaulich D; Hudelist G; Koestler WJ; Czerwenka K; Mueller R; Helmy S; Ruecklinger E; Kubista E; Singer CF
    Oncol Rep; 2005 Aug; 14(2):305-11. PubMed ID: 16012707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.